<DOC>
	<DOCNO>NCT01173627</DOCNO>
	<brief_summary>The purpose study evaluate oral bioequivalence Mallinckrodt test fentanyl citrate oral transmucosal 400 mcg troche compare Actiq 400 mcg ( Cephalon , Inc. ) fast condition .</brief_summary>
	<brief_title>Bioequivalence Test Troche Formulation Fentanyl Citrate ( 400 mcg ) Compared Actiq® 400 mcg , Cephalon , Inc .</brief_title>
	<detailed_description>Fentanyl opioid analgesic pharmacological effect similar morphine . Fentanyl interact predominately opioid µ-receptor . In clinical setting , fentanyl exerts principal pharmacologic effect central nervous system . The fentanyl citrate oral transmucosal troche , Actiq ( Cephalon , Inc. ) , indicate management breakthrough cancer pain patient malignancy already receive tolerant prior therapy underlie persistent cancer pain .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Males nonpregnant , nonlactating female , 18 year age old minimum body weight 120 pound body mass index ( BMI ) 19 29 inclusive . Female subject must postmenopausal least one year , surgically sterile , use reliable method contraception ( oral , transdermal , injectable hormonal contraceptive ; condom spermicide ; IUD ; abstinence , etc . ) least 30 day prior duration study participation . Normal , healthy status confirm require screening assessment . Subjects must able provide write consent agree abide study requirement . Subjects must able demonstrate understand perform dose procedure correctly use placebo troche checkin Period 1 . If female , positive pregnancy test time study , pregnant , lactating , likely become pregnant study . Female subject childbearing potential used adequate form birth control within 30 day dose . History condition might contraindicate require caution use administration fentanyl naltrexone , include : renal impairment , hepatobiliary pancreatic disease , gastrointestinal obstruction , cardiac disease , obstructive pulmonary disease , acute severe bronchial asthma , hypercarbia , elevate intracranial pressure , deplete blood volume , paralytic ileus , hypersensitivity idiosyncratic reaction fentanyl , naltrexone , opioids . History drug allergy , hypersensitivity , intolerance would compromise safety subject study . History chronic alcohol , drug , narcotic abuse , chronic use tranquilizer , sedative , aspirin , antibiotic , medication . History malignancy , stroke , diabetes ; cardiac , renal , liver , pulmonary disease . History anxiety , tension , severe agitation , psychiatric disorder , psychosis , mental depression require hospitalization , psychotherapy , and/or medication . History diagnosis epilepsy seizure disorder . History abdominal and/or pelvic surgery within last 5 year , except elective surgical sterilization . History acute abdominal condition gastrointestinal disease include , limited , peptic ulcer , diverticulitis , bowel obstruction , adhesion , ileus , gastritis , chronic diarrhea . Subjects present acute illness . Administration investigational drug 30 day prior study entry . Subjects smoke use nicotinecontaining product within 6 month prior study entry . Donation significant loss whole blood ( 480 mL ) within 30 day plasma within 14 day prior study entry , include withdrawn conduct clinical study . Positive test result HIV , hepatitis B , hepatitis C. Positive test result drug abuse alcohol . Subjects take prescription drug , except hormonal contraception , within 14 day overthecounter medication ( include herbal preparation ) within 7 day prior study drug administration except standard daily dose multivitamin , exclude checkin Period 2 . Any subject experiencing adverse event 13 and/or 1 hour dos naltrexone , investigator 's opinion , indicative possible previous opioid use/abuse , would prevent tolerance additional dose naltrexone , withdrawn study prior dose fentanyl . Subjects dental brace partial denture . Subjects present history gum disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Fentanyl</keyword>
</DOC>